Trial site
Centre de Cancérologie du Grand Montpellier
Montpellier, Languedoc-roussillon 34070, FranceNot linked to an institution yet
- 12running trials
- 3closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Status
- Active, not recruiting9 trials
- Completed2 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company5 trials
- UNICANCER3 trials
- Merck Sharp & Dohme LLC2 trials
- Amgen1 trial
- Bristol-Myers Squibb1 trial
- and 3 more
Running trials
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Cristian Villanueva (principal investigator)
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220· Phase 1/2· Stemline Therapeutics, Inc.· Source
Active, not recruiting
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988· Phase 3· Dizal Pharmaceuticals· Source
Recruiting
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
NCT05378204· Institut Claudius Regaud· Source
Contact: Cristian VILLANUEVA
Active, not recruiting
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365· Phase 2/3· Eli Lilly and Company· Source
Active, not recruiting
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
NCT03143322· UNICANCER· Source
Active, not recruiting
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
NCT00967863· UNICANCER· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error